Immunotherapy for Renal Cell Carcinoma

Česká verzia

Authors: T. Büchler
Authors place of work: Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha
Published in the journal: Klin Onkol 2015; 28(Supplementum 4): 64-68
Category: Specials
doi: https://doi.org/10.14735/amko20154S64

Summary

Background:
Renal cell carcinoma is characterised by chemo and radioresistance. Although drugs targeting angiogenesis and intracellular signaling have become the mainstay of systemic therapy for renal cell carcinoma in the last decade, latest immunotherapeutic approaches have achieved promising results.

Aim:
To review the development of immunotherapy for renal cell carcinoma, especially the results of published studies using novel immunotherapeutic agents including checkpoint inhibitors.

Results:
It has long been known that nonspecific immunotherapy may result in long term complete remission in a small number of patients. Advances in immunology have led to the renewal of interest in the use of anticancer immunotherapy for metastatic renal cell carcinoma. Promising results in phase I and II studies have been achieved using monoclonal antibodies against PD‑ 1 receptor and its ligand. Studies comparing immunotherapy to standard targeted therapies are ongoing.

Key words:
renal cell carcinoma – immunology – immunotherapy

Supported by grant VES 2015 15-34678A from the Agency for Healthcare Research, Ministry of Health, Czech Republic.

The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
20. 7. 2015

Accepted:
17. 8. 2015

Zdroje

1. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice [monograph on the Internet]. Masarykova univerzita, Česká republika; 2005 [citováno 2015 June 29]. Dostupný z: http:/ / www.svod.cz.

2. Dušek L, Mužík J, Malúšková D et al. Incidence a mortalita nádorových onemocnění v České republice. Klin Onkol 2014; 27(6): 406– 423. doi: 10.14735/ amko2014406.

3. Terme M, Colussi O, Marcheteau E et al. Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol 2012; 2012: 492920. doi: 10.1155/ 2012/ 492920.

4. Shrimali RK, Yu Z, Theoret MR et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70(15): 6171– 6180. doi: 10.1158/ 0008‑ 5472.CAN‑ 10‑ 0153.

5. Wang Y, Sparwasser T, Figlin R et al. Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition. Cancer Res 2014; 74(8): 2217– 2228. doi: 10.1158/ 0008‑ 5472.CAN‑ 13‑ 2928.

6. Bumpus HC. The apparent disappearance of pulmonary metastasis in a case of hypernephroma following nephrectomy. J Urol 1928; 20: 185– 191.

7. Melichar B, Vanecková J, Morávek P et al. Spontaneous regression of renal cell carcinoma lung metastases in a patient with psoriasis. Acta Oncol 2009; 48(6): 925– 927. doi: 10.1080/ 02841860902882451.

8. Rothermundt CA, Omlin A, Gillessen S. Sunitinib with-drawal phenomenon or spontaneous regression in renal cell cancer. Ann Oncol 2009; 20(6): 1144– 1146. doi: 10.1093/ annonc/ mdp239.

9. van der Vliet HJ, Koon HB, Yue SC et al. Effects of the administration of high‑dose interleukin‑2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res 2007; 13(7): 2100– 2108.

10. Ahmadzadeh M, Rosenberg SA. IL‑2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107(6): 2409– 2414.

11. Carvallo C, Childs R. Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors. Cytotechnology 2003; 41(2– 3): 197– 206. doi: 10.1023/ A:1024839225920.

12. Figlin RA, Thompson JA, Bukowski RM et al. Multicenter, randomized, phase III trial of CD8(+) tumor‑ infiltrating lymphocytes in combination with recombinant interleukin‑2 in metastatic renal cell carcinoma. J Clin Oncol 1999; 17(8): 2521– 2529.

13. Bedke J, Kruck S, Gakis G et al. Checkpoint modulation – a new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother 2015; 11(5): 1201– 1208. doi: 10.1080/ 21645515.2015.1016657.

14. Motzer RJ, Rini BI, McDermott DF et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015; 33(13): 1430– 1437. doi: 10.1200/ JCO.2014.59.0703.

15. Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti‑CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30(8): 825– 830.

16. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti‑PD‑ L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366(26): 2455– 2465. doi: 10.1056/ NEJMoa1200694.

17. McDermott DF, Sznol M, Sosman JA et al. Immune correlates and long term follow up of a phase Ia study of MPDL3280A, an engineered PD‑ L1 antibody, in patients with metastatic renal cell carcinoma (mRCC). Ann Oncol 2014; 25 (Suppl 4): iv280.

18. Plimack ER, Hammers HJ, Rini BI. Updated survival results from a randomized, dose‑ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2015; 33 (Suppl): abstr. 4553.

19. Hammers HJ, Plimack ER, Infante JR et al. Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2015; 33 (Suppl): abstr. 4516.

20. Choueiri TK, Fishman NM, Escudier B. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): association of biomarkers with clinical outcomes. J Clin Oncol 2015; 33 (Suppl): abstr. 4500.

21. Sznol M, McDermott DF, Fields Jones S. Phase Ib evaluation of in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2015; 33 (Suppl 7): abstr. 410.

22. Amin A, Dudek AZ, Logan TF et al. Survival with AGS‑ 003, an autologous dendritic cell‑based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2study results. J Immunother Cancer 2015; 3: 14. doi: 10.1186/ s40425‑ 015‑ 0055‑ 3.

23. Belldegrun AS, Chamie K, Kloepfer P et al. ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high‑risk ccRCC – results and implications for adjuvant clinical trials. J Clin Oncol 2013; 31 (Suppl): abstr. 4507.